9,501 results match your criteria Natriuretic Peptides in Congestive Heart Failure


Beyond clinical examination and natriuretic peptides: comprehensive quantification of congestion with ultrasound in ambulatory heart failure patients.

Eur J Heart Fail 2019 Feb 18. Epub 2019 Feb 18.

Department of Emergency Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1422DOI Listing
February 2019

NT-pro-BNP correlates with disease severity and predicts outcome in cerebral haemorrhage patients: Cohort study.

J Neurol Sci 2019 Feb 8;399:51-56. Epub 2019 Feb 8.

Internal Medicine Department, São João Hospital Centre, Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal; Stroke Unit, São João Hospital Centre, Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal; Department of Surgery and Physiology, Faculty of Medicine, University of Porto, Alameda Prof. Hernani Monteiro, 4200-319 Porto, Portugal.

Background: Intracerebral haemorrhage (ICH) is a devastating condition, with more than half of patients dying or becoming dependent after such an event. Natriuretic peptides, frequently used in the management of heart failure, have been shown to correlate with disease severity and prognosis in brain disorders. The aim of this study was to test the hypothesis that NT-pro-BNP correlates with disease severity and is an independent prognostic marker for non-traumatic ICH patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jns.2019.02.014DOI Listing
February 2019

Non-familial cardiomyopathies in Lebanon: exome sequencing results for five idiopathic cases.

BMC Med Genomics 2019 Feb 14;12(1):33. Epub 2019 Feb 14.

Department of Biochemistry and Molecular Genetics, American University of Beirut Faculty of Medicine and Medical Center (AUBMC), Phase I, 8th floor, Room C-823, PO Box 11-0236, Riad El-Solh, Beirut, 1107 2020, Lebanon.

Background: Cardiomyopathies affect more than 0.5% of the general population. They are associated with high risk of sudden cardiac death, which can result from either heart failure or electrical abnormalities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12920-019-0478-7DOI Listing
February 2019

The Role of Troponin for Acute Heart Failure.

Curr Heart Fail Rep 2019 Feb 14. Epub 2019 Feb 14.

Department of Emergency Medicine, Wayne State University School of Medicine, Detroit, MI, USA.

Purpose Of Review: To review the mechanisms, clinical interpretation, prognostic role, and future research regarding cardiac troponin (cTn) in the assessment of acute heart failure (AHF) patients presenting to the emergency department (ED).

Recent Findings: cTn has become a necessary component of the evaluation of AHF patients in the ED, largely because of its independently predictive value as a prognosticator of poor outcome. High-sensitivity assays (hs-cTn) may add risk stratification value beyond conventional assays, specifically with regard to identifying low-risk AHF patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11897-019-0420-5DOI Listing
February 2019

Potential and Limitations of Atrial Natriuretic Peptide as Biomarker in Pediatric Heart Failure-A Comparative Review.

Front Pediatr 2018 29;6:420. Epub 2019 Jan 29.

Institute of Clinical Pharmacy and Pharmacotherapy, Heinrich-Heine-University, Düsseldorf, Germany.

Although B-type Natriuretic Peptide (BNP), N-terminal-proBNP (NT-proBNP), and mid-regional-proANP (MR-proANP) are included in current guidelines on heart failure in adults, no guideline considering these biomarkers in pediatric heart failure is available. A new drug class of neprilysin inhibitors as fixed-dose combination (Sacubitril/valsartan) has been introduced and is currently being investigated in children suffering from heart failure. Atrial Natriuretic Peptide (ANP) is discussed as a more useful alternative to BNP because it may grants better insights into the effects of this treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fped.2018.00420DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361796PMC
January 2019

Heart Failure in the diabetic patient - epidemiology, etiology, prognosis, therapy and the effect of glucose lowering medications.

Diabetes Obes Metab 2019 Feb 5. Epub 2019 Feb 5.

Southside Endocrinology and Diabetes & Thyroid Associates, Birmingham, AL.

In the type 2 diabetic patient the frequency of heart failure (HF) is increased and the mortality from HF is higher than with non-diabetic HF. The increased frequency of HF is due to the cardiotoxic tetrad of ischemic heart disease, left ventricular hypertrophy, diabetic cardiomyopathy and an extracellular volume expansion resistant to atrial natriuretic peptides. Activation of the RAAS and sympathetic nervous systems results in cardiac remodeling, which worsens cardiac function. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dom.13652DOI Listing
February 2019
1 Read

Prognostic implications of plasma volume status estimates in heart failure with preserved ejection fraction: insights from TOPCAT.

Eur J Heart Fail 2019 Feb 4. Epub 2019 Feb 4.

Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.

Aims: Plasma volume expansion is clinically and prognostically relevant in individuals with heart failure. Prior cohorts either excluded or had limited representation of patients with heart failure with preserved ejection fraction (HFpEF). We aimed to examine the relationship between calculated plasma volume status (PVS) and outcomes in HFpEF. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1407DOI Listing
February 2019

Soluble neprilysin does not correlate with prognosis in pulmonary hypertension.

ESC Heart Fail 2019 Jan 25. Epub 2019 Jan 25.

Department of Cardiovascular Medicine, Fukushima Medical University, 1 Hikarigaoka, Fukushima, 960-1295, Japan.

Aims: It has been reported that circulating soluble neprilysin (sNEP), which catalyses the degradation of several vasodilator peptides such as natriuretic peptides, predicts prognosis in heart failure patients with reduced ejection fraction. Hypoxia-induced decrease in NEP expression in lungs has been reported. However, the associations between sNEP and haemodynamic parameters, as well as the prognostic impact of sNEP in pulmonary hypertension (PH), remain unclear. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ehf2.12404
Publisher Site
http://dx.doi.org/10.1002/ehf2.12404DOI Listing
January 2019
4 Reads

Prediction of incident heart failure by serum amino-terminal pro-B-type natriuretic peptide level in a community-based cohort.

Eur J Heart Fail 2019 Jan 18. Epub 2019 Jan 18.

University of Melbourne, Parkville, Australia.

Aims: We investigated which serum amino-terminal pro-B-type-natriuretic peptide (NT-proBNP) levels inform heart failure (HF) risk in a community-based population at increased cardiovascular disease (CVD) risk.

Methods And Results: Inclusion criteria were age ≥ 60 years with one or more of self-reported hypertension, diabetes, heart disease, abnormal heart rhythm, cerebrovascular disease, or renal impairment. Exclusion criteria were known HF, ejection fraction (EF) < 50%, or more than mild valve abnormality. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1381DOI Listing
January 2019
2 Reads

Heart failure and chronic obstructive pulmonary disease: a review.

Acta Cardiol 2019 Jan 16:1-8. Epub 2019 Jan 16.

a Internal Medicine Clinic , Clinical Emergency Hospital of Bucharest , Bucharest , Romania.

Heart failure (HF) and chronic obstructive pulmonary disease (COPD) are important causes of morbidity and mortality worldwide. The association between the two conditions have significant systemic effects and a chronic, progressive evolution, affecting exercise tolerance and quality of life. The diseases share common risk factors, such as smoking, advanced age, and low-grade systemic inflammation. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/00015385.2018.1
Publisher Site
http://dx.doi.org/10.1080/00015385.2018.1559485DOI Listing
January 2019
4 Reads

Prognostic value of short-term follow-up B-type natriuretic peptide levels after hospital discharge in patients with acute myocardial infarction.

Int J Cardiol 2019 Jan 8. Epub 2019 Jan 8.

Division of Cardiology, Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea. Electronic address:

Background: Elevated B-type natriuretic peptide (BNP) levels in patients hospitalized for acute myocardial infarction (AMI) are associated with heart failure and mortality. However, the role of BNP after hospital discharge is not clear. Therefore, we assessed the relationship between short-term follow-up BNP levels and clinical outcomes including all-cause mortality and major adverse cardiovascular events (MACE) in patients with AMI after hospital discharge. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijcard.2019.01.026DOI Listing
January 2019

Qishenyiqi dripping pill improves ventricular remodeling and function in patients with chronic heart failure: A pooled analysis.

Medicine (Baltimore) 2019 Jan;98(2):e13906

Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences, State and Shandong Province Joint Key Laboratory of Translational Cardiovascular Medicine, Department of Cardiology, Shandong University Qilu Hospital, School of Basic Medical Sciences of Shandong University.

Background: Qishenyiqi dripping pill for chronic heart failure (CHF) remains controversial due to lack of high-quality trials. Therefore, we conduct this pooled-analysis to evaluate the efficacy and safety of Qishenyiqi in CHF patients.

Methods: We searched for randomized clinical trials for Qishenyiqi dripping pill in treating CHF up to August 2018 through China National Knowledge Infrastructure (CNKI), the PubMed Database, the Wanfang Database, the China Scientific Journal Database (VIP), and the Chinese Biomedicine Literature Service System. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000013906DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336621PMC
January 2019
8 Reads

Biomarker developments in heart failure: 2016 and beyond.

Curr Opin Cardiol 2019 Mar;34(2):218-224

Division of Cardiology, University of California, San Diego, La Jolla, California, USA.

Purpose Of Review: Biomarkers play a fundamental role in the management of heart failure. Both new and old biomarkers are evaluated every year with new information gained for their use in heart failure. Major advancements have been made in the past 2 years in key biomarkers that will surely become part of standard clinical management of heart failure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/HCO.0000000000000596DOI Listing
March 2019
1 Read

Serum levels of carbohydrate antigen 125 in combination with N-terminal pro-brain natriuretic peptide in patients with acute decompensated heart failure.

Korean J Intern Med 2018 Dec 31. Epub 2018 Dec 31.

Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Korea.

Background/aims: Carbohydrate antigen 125 (CA-125) is an emerging prognostic biomarker for heart failure. We aimed to test the long-term prognostic value of CA-125 in combination with N-terminal pro-brain natriuretic peptide (NT-proBNP) in patients with acute decompensated heart failure (ADHF).

Methods: This observational study included a total of 413 patients (64. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3904/kjim.2017.313DOI Listing
December 2018

NT-proBNP Goal Achievement Is Associated With Significant Reverse Remodeling and Improved Clinical Outcomes in HFrEF.

JACC Heart Fail 2019 Feb 2;7(2):158-168. Epub 2019 Jan 2.

Duke University Medical Center, Durham, North Carolina; Duke Clinical Research Institute, Durham, North Carolina.

Objectives: This study aims to assess the association between biomarker-guided therapy and left ventricular (LV) remodeling.

Background: In patients with heart failure with reduced ejection fraction (HFrEF), it is unclear if lowering natriuretic peptides reflects structural and functional changes in the heart. This study aims to assess the association between biomarker-guided therapy and left ventricular (LV) remodeling. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S22131779183078
Publisher Site
http://dx.doi.org/10.1016/j.jchf.2018.10.014DOI Listing
February 2019
1 Read

Higher plasma levels of CT-proAVP are linked to less anxiety in men but not women with cardiovascular risk factors: Results from the observational Diast-CHF study.

Psychoneuroendocrinology 2019 Mar 20;101:272-277. Epub 2018 Dec 20.

Department of Psychosomatic Medicine and Psychotherapy, University of Göttingen Medical Center, Göttingen, Germany; German Center for Cardiovascular Research (DZHK), partner site Göttingen, Germany.

Aim: Using data from the multicenter, observational Diast-CHF (Diagnostic Trial on Prevalence and Clinical Course of Diastolic Dysfunction and Heart Failure) study, this post-hoc analysis aimed at assessing the association between serum concentrations of C-terminal pro-arginine vasopressin (CT-proAVP) and anxiety in patients with cardiovascular risk factors.

Background: Animal studies have demonstrated that centrally released AVP is involved in the development of anxiety-like behaviors, however, it is unknown whether, also in humans, CT-proAVP used as a proxy for the co-secreted AVP is associated with self-reported anxiety.

Methods: In 1463 study participants with cardiovascular risk factors (mean age 66. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.psyneuen.2018.12.230DOI Listing
March 2019
1 Read

ST2 elevation in heart failure, predictive of a high early mortality.

Indian Heart J 2018 Nov - Dec;70(6):822-827. Epub 2018 Aug 31.

VA Medical Centre, University of California, San Diego, USA. Electronic address:

Background: Soluble suppression of tumorigenicity-2 (sST2) is a novel biomarker shown to be useful for prognostic assessment in heart failure (HF). However, very limited data exists about its prognostic utility in patients with HF in India.

Methods: We studied 150 patients [mean age 67. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00194832183017
Publisher Site
http://dx.doi.org/10.1016/j.ihj.2018.08.019DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6306350PMC
January 2019
3 Reads

Can Circulating B-Type Natriuretic Peptide Concentrations Guide Treatment of Obstructive Left Main Coronary Artery Disease?

Authors:
Torbjørn Omland

Circulation 2018 Jul;138(5):479-482

Division of Medicine, Akershus University Hospital, Lørenskog, Norway and Center for Heart Failure Research, Institute of Clinical Medicine, University of Oslo, Norway.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/CIRCULATIONAHA.118.035272DOI Listing

The tip of the iceberg: finding patients with heart failure with preserved ejection fraction in primary care. An observational study.

BJGP Open 2018 Oct 19;2(3):bjgpopen18X101606. Epub 2018 Sep 19.

Consultant Cardiologist, Department of Medicine, James Paget University Hospital, Gorleston-on-Sea, UK.

Background: Heart failure with preserved ejection fraction (HFpEF) is under-identified in primary care.

Aim: The aim of this study was to determine what information is available in patients' primary care practice records that would identify patients with HFpEF.

Design & Setting: Record review in two practices in east of England. Read More

View Article

Download full-text PDF

Source
http://bjgpopen.org/lookup/doi/10.3399/bjgpopen18X101606
Publisher Site
http://dx.doi.org/10.3399/bjgpopen18X101606DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189778PMC
October 2018
10 Reads

The conundrum of patients with obesity, exercise intolerance, elevated ventricular filling pressures and a measured ejection fraction in the normal range.

Authors:
Milton Packer

Eur J Heart Fail 2019 Feb 18;21(2):156-162. Epub 2018 Dec 18.

Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX, USA.

Patients with obesity, a reduced exercise capacity, increased cardiac filling pressures and a measured left ventricular ejection fraction in the normal range do not have a homogeneous disorder, but instead, exhibit one of three phenotypes. First, many obese people exhibit sodium retention, plasma volume expansion and cardiac enlargement, and some are likely to have heart failure that is related to hypervolaemia, even though cardiac index and circulating levels of natriuretic peptides are not meaningfully increased. Second, in some middle-aged men and women (particularly those with minimal co-morbidities), levels of natriuretic peptides increase markedly and can lower systemic vascular resistance, thus leading to high-output heart failure (HOHF) and glomerular hyperfiltration. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1377DOI Listing
February 2019
1 Read

Use of levosimendan in acute heart failure.

Eur Heart J Suppl 2018 Dec 11;20(Suppl I):I2-I10. Epub 2018 Dec 11.

Second Cardiology Department and Heart Failure Unit, Attikon Teaching Hospital, Athens, Greece.

As a calcium sensitizer and inodilator that augments cardiac contractility without increasing myocardial oxygen demand or exacerbating ischaemia, levosimendan may be well configured to deliver inotropic support in cases of acute heart failure (AHF). Other factors favouring levosimendan in this setting include its extended duration of action due to the formation of an active metabolite and the lack of any attenuation of effect in patients treated with beta-blockers. Effects of levosimendan on systemic haemodynamics include its significant, dose-dependent increases in cardiac output, stroke volume and heart rate, and decreases in right and left ventricular filling and total peripheral resistance. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/eurheartj/suy039DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6288642PMC
December 2018
3 Reads

Natriuretic peptides in heart failure: Current achievements and future perspectives.

Int J Cardiol 2018 Dec 10. Epub 2018 Dec 10.

Department of Clinical and Molecular Medicine, School of Medicine and Psychology, Sapienza University of Rome, Rome, Italy; IRCCS Neuromed, Pozzilli, Italy.

The last two centuries have witnessed countless discoveries in the field of medicine that found their roots in the up growing development of technology as well as in the visionary ideas of brilliant scientists and research groups. One of the most important discoveries in the field of cardiovascular medicine allowed to break the paradigm identifying the heart with mere mechanical pump and to characterize its intriguing endocrine properties. Indeed, the discovery of hormones produced by the cardiac chambers, the natriuretic peptides, represents one of the milestones of the current conception of complexity of integrated human physiology. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01675273183016
Publisher Site
http://dx.doi.org/10.1016/j.ijcard.2018.04.045DOI Listing
December 2018
11 Reads
4.036 Impact Factor

Combined Use of Circulating miR-133a and NT-proBNP Improves Heart Failure Diagnostic Accuracy in Elderly Patients.

Med Sci Monit 2018 Dec 7;24:8840-8848. Epub 2018 Dec 7.

Department of Gereology and Cardiology, Shanghai University of Medicine and Health Sciences Affiliated Zhoupu Hospital, Shanghai, China (mainland).

BACKGROUND Circulating microRNAs (miRNAs) are emerging as novel biomarkers for detecting cardiovascular diseases. Here, circulating miR-133a and miR-221 were investigated as potential diagnostic biomarkers for heart failure (HF) patients, particularly in elderly patients. MATERIAL AND METHODS A total of 94 elderly HF patients (mean age=77. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12659/MSM.911632DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6294044PMC
December 2018
1 Read

Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study.

Eur J Heart Fail 2018 Dec 6. Epub 2018 Dec 6.

Inserm UMR-S 942, Lariboisière Hospital, Paris, France.

Aim: This study aimed at evaluating the effects of sacubitril/valsartan on neprilysin (NEP), and the metabolism of natriuretic peptides in heart failure (HF) and providing additional mechanistic information on the mode of action of the drug.

Methods And Results: We enrolled 73 chronic HF patients who were switched from angiotensin-converting enzyme inhibitor or angiotensin receptor blocker to sacubitril/valsartan. In addition to clinical and echocardiographic assessment, plasma biomarkers were measured at baseline, day 30 and day 90 after initiation of treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1342DOI Listing
December 2018
56 Reads

Natriuretic Peptide Processing in Patients with and Without Left Ventricular Dysfunction.

Int Heart J 2019 Jan 5;60(1):115-120. Epub 2018 Dec 5.

Cardiovascular Center, Onze Lieve Vrouw Ziekenhuis.

This study aimed to examine the relationship between corin expression and circulating brain natriuretic peptide in patients with left ventricular (LV) dysfunction.Circulating levels of B-type natriuretic peptide (BNP) can be an indicator of LV dysfunction. The 32-amino-acid BNP is cleaved by corin, a cardiac serine protease, from its108-amino-acid pro-brain natriuretic peptide (proBNP) precursor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1536/ihj.18-012DOI Listing
January 2019
9 Reads

High doses of ANP and BNP exacerbate lipolysis in humans and the lipolytic effect of BNP is associated with cardiac triglyceride content in pigs.

Peptides 2019 Feb 30;112:43-47. Epub 2018 Nov 30.

Department of Clinical Biochemistry, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark; Department of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark; Department of Cardiorenal physiology (Mayo Clinic, Rochester, MN, USA; Copenhagen University, Denmark.

Drugs facilitating the cardioprotective effects of natriuretic peptides are introduced in heart failure treatment. ANP and BNP also stimulate lipolysis and increase circulating concentrations of free fatty acids (FFAs); an aspect, however, thought to be confined to primates. We examined the lipolytic effect of natriuretic peptide infusion in healthy young men and evaluated the effect in a porcine model of myocardial ischemia and reperfusion. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.peptides.2018.11.003DOI Listing
February 2019
2 Reads

Sacubitril/valsartan (LCZ696) significantly reduces aldosterone and increases cGMP circulating levels in a canine model of RAAS activation.

Eur J Pharm Sci 2019 Feb 30;128:103-111. Epub 2018 Nov 30.

Novartis Institutes for BioMedical Research, East Hanover, NJ, USA.

Simultaneous blockade of angiotensin receptors and enhancement of natriuretic peptides (NP) by the first-in-class angiotensin receptor neprilysin (NEP) inhibitor sacubitril/valsartan constitutes an effective approach to treating heart failure. This study examined the effects of sacubitril/valsartan (225 and 675 mg/day) vs. placebo, sacubitril (360 mg/day), valsartan (900 mg/day), and benazepril (5 mg/day) on the dynamics of the renin-angiotensin-aldosterone system (RAAS) and the NP system in dogs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejps.2018.11.037DOI Listing
February 2019
1 Read

Optimising standards of care of heart failure in general practice the OSCAR-HF pilot study protocol.

Acta Cardiol 2018 Dec 3:1-9. Epub 2018 Dec 3.

a Department of Public Health and Primary Care , KU Leuven (KUL) , Leuven , Belgium.

Background: Heart failure (HF) imposes a burden for patients and health economics. General practitioners (GPs) are confronted with the broadest range of HF management. Although guidelines exist, they are not fully implemented in the Belgian health care system. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/00015385.2018.1507426DOI Listing
December 2018
4 Reads

Natural and synthetic peptides in the cardiovascular diseases: An update on diagnostic and therapeutic potentials.

Arch Biochem Biophys 2019 Feb 24;662:15-32. Epub 2018 Nov 24.

Department of Pharmacy, University Federico II of Naples, Via D. Montesano 49, 80131, Naples, Italy. Electronic address:

Several peptides play an important role in physiological and pathological conditions into the cardiovascular system. In addition to well-known vasoactive agents such as angiotensin II, endothelin, serotonin or natriuretic peptides, the vasoconstrictor Urotensin-II (Uro-II) and the vasodilators Urocortins (UCNs) and Adrenomedullin (AM) have been implicated in the control of vascular tone and blood pressure as well as in cardiovascular disease states including congestive heart failure, atherosclerosis, coronary artery disease, and pulmonary and systemic hypertension. Therefore these peptides, together with their receptors, become important therapeutic targets in cardiovascular diseases (CVDs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.abb.2018.11.021DOI Listing
February 2019
1 Read

Analytical barriers in clinical B-type natriuretic peptide measurement and the promising analytical methods based on mass spectrometry technology.

Clin Chem Lab Med 2018 Nov 24. Epub 2018 Nov 24.

Division of Chemical Metrology and Analytical Science, National Institute of Metrology, Beijing, PR China.

B-type natriuretic peptide (BNP) is a circulating biomarker that is mainly applied in heart failure (HF) diagnosis and to monitor disease progression. Because some identical amino acid sequences occur in the precursor and metabolites of BNP, undesirable cross-reactions are common in immunoassays. This review first summarizes current analytical methods, such as immunoassay- and mass spectrometry (MS)-based approaches, including the accuracy of measurement and the inconsistency of the results. Read More

View Article

Download full-text PDF

Source
http://www.degruyter.com/view/j/cclm.ahead-of-print/cclm-201
Publisher Site
http://dx.doi.org/10.1515/cclm-2018-0956DOI Listing
November 2018
8 Reads

Hyperoside Protects Against Pressure Overload-Induced Cardiac Remodeling via the AKT Signaling Pathway.

Cell Physiol Biochem 2018 22;51(2):827-841. Epub 2018 Nov 22.

Background/aims: Cardiac hypertrophy is a major predisposing factor for heart failure and sudden cardiac death. Hyperoside (Hyp), a flavonoid isolated from Rhododendron ponticum L., is a primary component of Chinese traditional patent medicines. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000495368DOI Listing
December 2018
9 Reads

Soluble ST2 for Prediction of Clinical Outcomes in Patients with ST-Segment Elevation Myocardial Infarction Receiving Primary PCI.

Int Heart J 2019 Jan 20;60(1):19-26. Epub 2018 Nov 20.

Laboratory of Molecular Cardiology, Wuhan Asia Heart Hospital, Wuhan University.

Soluble suppression of tumorigenicity 2 (sST2), a biomarker representing myocardial fibrosis and inflammation, has been applied in risk stratification of patients with myocardial infarction (MI). However, whether primary PCI (PPCI) will eliminate the predictive value of sST2 in STEMI patients has not been well studied. Here, we conducted a prospective clinical trial to evaluate the correlation between sST2 and prognosis in STEMI patients undergoing PPCI. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1536/ihj.18-020DOI Listing
January 2019
10 Reads

Novel biomarkers of cardiovascular disease: Applications in clinical practice.

Crit Rev Clin Lab Sci 2019 Jan 20;56(1):33-60. Epub 2018 Nov 20.

a Division of Medicine , Akershus University Hospital , Lørenskog , Norway.

Measurement of biomarkers has revolutionized the work-up of patients with suspected cardiovascular disease. The most widely used contemporary cardiovascular biomarkers are the natriuretic peptides in the diagnosis and prognosis of heart failure and cardiac troponins in the diagnosis of acute myocardial infarction. Numerous other biomarkers pertaining to diagnosis, prognosis, and risk prediction have been identified, but few have made their way to clinical practice. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/10408363.2018.1
Publisher Site
http://dx.doi.org/10.1080/10408363.2018.1525335DOI Listing
January 2019
13 Reads

Diagnosis of heart failure: the new classification of heart failure.

Vnitr Lek 2018 ;64(9):847-851

Heart failure (HF) is a clinical syndrome characterized by typical symptoms (e.g. breathlessness, ankle swelling and fatigue) that may be accompanied by signs (e. Read More

View Article

Download full-text PDF

Source
January 2018
17 Reads

Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial.

Lancet 2019 01 11;393(10166):61-73. Epub 2018 Nov 11.

Cardiovascular Research Centre and Cardiovascular Magnetic Resonance Unit, Royal Brompton Hospital, London, UK; National Heart and Lung Institute, Imperial College London, London, UK. Electronic address:

Background: Patients with dilated cardiomyopathy whose symptoms and cardiac function have recovered often ask whether their medications can be stopped. The safety of withdrawing treatment in this situation is unknown.

Methods: We did an open-label, pilot, randomised trial to examine the effect of phased withdrawal of heart failure medications in patients with previous dilated cardiomyopathy who were now asymptomatic, whose left ventricular ejection fraction (LVEF) had improved from less than 40% to 50% or greater, whose left ventricular end-diastolic volume (LVEDV) had normalised, and who had an N-terminal pro-B-type natriuretic peptide (NT-pro-BNP) concentration less than 250 ng/L. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(18)32484-XDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6319251PMC
January 2019
2 Reads

Evaluation of analytical performances using standardized analytical protocols and comparison of clinical results of the new ADVIA BNP and NT-proBNP immunoassays for the Centaur XPT platform.

Clin Chem Lab Med 2018 Nov 9. Epub 2018 Nov 9.

Scuola, Superiore Sant'Anna, Department of Laboratory Medicine, Fondazione G. Monasterio CNR - Regione Toscana, Via Giuseppe Moruzzi 1, 56124 Pisa, Italy.

Background The study aim was to evaluate and compare analytical performances and clinical results of ADVIA BNP and PBNP methods using the Centaur XPT platform with those of Access BNP, using the DxI platform and the ECLIA NT-proBNP method, using the Cobas e411 platform, respectively. Methods Limits of blank (LoB), detection (LoD) and quantitation (LoQ) at 20% CV and 10% CV were evaluated according to international standardized protocols. The analytical parameters were assessed throughout a 90-working-day period using three curve calibrations. Read More

View Article

Download full-text PDF

Source
http://www.degruyter.com/view/j/cclm.ahead-of-print/cclm-201
Publisher Site
http://dx.doi.org/10.1515/cclm-2018-0760DOI Listing
November 2018
8 Reads

sST2 as a New Biomarker of Chronic Kidney Disease-Induced Cardiac Remodeling: Impact on Risk Prediction.

Mediators Inflamm 2018 8;2018:3952526. Epub 2018 Oct 8.

Département de Biochimie-Hormonologie, CHU Montpellier, Université de Montpellier, Montpellier, France.

Heart failure is the most frequent cardiac complication of chronic kidney disease (CKD). Biomarkers help identify high-risk patients. Natriuretic peptides (BNP and NT-proBNP) are largely used for monitoring patients with cardiac failure but are highly dependent on glomerular filtration rate (GFR). Read More

View Article

Download full-text PDF

Source
https://www.hindawi.com/journals/mi/2018/3952526/
Publisher Site
http://dx.doi.org/10.1155/2018/3952526DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6196921PMC
January 2019
6 Reads

B-type natriuretic peptides in pregnant women with normal heart or cardiac disorders.

Authors:
Alice Balaceanu

Med Hypotheses 2018 Dec 19;121:149-151. Epub 2018 Sep 19.

"Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania; "Sf. Ioan" Clinical Emergency Hospital, Internal Medicine Department, Romania. Electronic address:

Pregnancy is characterized by complex physiological changes of the cardiovascular system. B-type natriuretic peptides, represented by the bioactive molecule (BNP) and its inactive amino terminal fragment (NT-proBNP) are important biomarkers used in the management of the heart failure. Besides cardiac causes, BNP can grow in other noncardiac conditions such as pregnancy. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03069877183081
Publisher Site
http://dx.doi.org/10.1016/j.mehy.2018.09.034DOI Listing
December 2018
12 Reads

Nuanxin capsule for heart failure: A systematic review of randomized controlled trials.

Medicine (Baltimore) 2018 Nov;97(44):e12667

The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.

Objective: To assess the efficacy and safety of Nuanxin capsule for patients with heart failure (HF).

Methods: A systematic literature search was performed in 6 databases: PubMed, EMBASE, Chinese National Knowledge Infrastructure (CNKI), Wan-fang Data Information Site, Chinese BioMedical Database (CBM), VIP Chinese Science and Technique Journals Database from the date of its inception up to November 2016. Review Manager 5. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000012667DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6221618PMC
November 2018
3 Reads

Body Mass Index, Natriuretic Peptides, and Risk of Adverse Outcomes in Patients With Heart Failure and Preserved Ejection Fraction: Analysis From the TOPCAT Trial.

J Am Heart Assoc 2018 Nov;7(21):e009664

1 Division of Cardiology Department of Internal Medicine University of Texas Southwestern Medical Center Dallas TX.

Background The prognostic interrelationship between natriuretic peptide ( NP ) levels and body mass index ( BMI ) among patients with chronic stable heart failure with preserved ejection fraction is not well characterized. Methods and Results Participants from the TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) trial enrolled in the Americas meeting inclusion by the NP stratum were stratified into 4 data-derived categories by BMI and standardized NP -z score. Adjusted Cox-proportional models determined the independent association of BMI , NP -z score, and BMI / NP categories with composite primary end point, heart failure hospitalization, and all-cause mortality. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/JAHA.118.009664DOI Listing
November 2018

Characterisation of circulating biomarkers before and after cardiac resynchronisation therapy and their role in predicting CRT response: the COVERT-HF study.

Open Heart 2018 18;5(2):e000899. Epub 2018 Oct 18.

Department of Cardiology, University Hospital Coventry and Warwickshire NHS Trust, Coventry, UK.

Aims: Cardiac resynchronisation therapy (CRT) is effective treatment for selected patients with heart failure (HF) but has ~30% non-response rate. We evaluated whether specific biomarkers can predict outcome.

Methods: A prospective single-centre pilot study of consecutive unselected patients undergoing CRT for HF between November 2013 and December 2015 evaluating cardiac extracellular matrix biomarkers and micro-ribonucleic acid (miRNA) expression before and after CRT assessing ability to predict functional response and survival. Read More

View Article

Download full-text PDF

Source
http://openheart.bmj.com/lookup/doi/10.1136/openhrt-2018-000
Publisher Site
http://dx.doi.org/10.1136/openhrt-2018-000899DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6196945PMC
October 2018
8 Reads

Essential components in natriuretic peptide-guided management of heart failure: an intervention synthesis.

Open Heart 2018 8;5(2):e000826. Epub 2018 Oct 8.

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.

Aim: To identify the key components of natriuretic peptide (NP)-guided treatment interventions which reduced hospitalisation in patients with heart failure (HF).

Methods And Results: We extracted detailed information on the components of interventions from studies of NP-guided treatment of HF identified in a previous systematic review. We used meta-regression techniques to assess univariate associations between components and the strength of the reduction in HF hospitalisations and all-cause mortality. Read More

View Article

Download full-text PDF

Source
http://openheart.bmj.com/lookup/doi/10.1136/openhrt-2018-000
Publisher Site
http://dx.doi.org/10.1136/openhrt-2018-000826DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6196949PMC
October 2018
8 Reads

Established and Emerging Roles of Biomarkers in Heart Failure.

Circ Res 2018 Aug;123(5):614-629

From the Cardiology Division, Massachusetts General Hospital, Boston (N.E.I., J.L.J.).

Heart failure (HF) is a complex syndrome with an enormous societal burden in terms of cost, morbidity, and mortality. Natriuretic peptide testing is now widely used to support diagnosis, prognostication, and management of patients with HF and are incorporated into HF clinical practice guidelines. Beyond the natriuretic peptides, novel biomarkers may supplement traditional clinical and laboratory testing to improve understanding of the complex disease process of HF and possibly to personalize care for those affected through better individual phenotyping. Read More

View Article

Download full-text PDF

Source
https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.118.31270
Publisher Site
http://dx.doi.org/10.1161/CIRCRESAHA.118.312706DOI Listing
August 2018
12 Reads

Biomarkers in the diagnosis of pleural diseases: a 2018 update.

Authors:
José M Porcel

Ther Adv Respir Dis 2018 Jan-Dec;12:1753466618808660

Pleural Medicine Unit, Department of Internal Medicine, Arnau de Vilanova University Hospital, Avda Alcalde Rovira Roure 80, 25198 Lleida, Spain.

The use of biomarkers on pleural fluid (PF) specimens may assist the decision-making process and enhance clinical diagnostic pathways. Three paradigmatic examples are heart failure, tuberculosis and, particularly, malignancy. An elevated PF concentration of the amino-terminal fragment of probrain natriuretic peptide (>1500 pg/ml) is a hallmark of acute decompensated heart failure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1753466618808660DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6204620PMC
October 2018
14 Reads

Nesiritide and Me.

Circ Heart Fail 2018 Aug;11(8):e005440

Division of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/CIRCHEARTFAILURE.118.005440DOI Listing

IL-1 Blockade in Patients With Heart Failure With Preserved Ejection Fraction.

Circ Heart Fail 2018 Aug;11(8):e005036

Division of Cardiology, Virginia Commonwealth University Pauley Heart Center, Richmond (B.W.V.T., C.R.T., J.C., S.C., D.K., M.G.D.B., H.B., G.W., M.V., C.O.-E., N.A.A., D.D., A.A.).

Background Enhanced inflammation may lead to exercise intolerance in heart failure with preserved ejection fraction. The aim of the current study was to determine whether IL (interleukin)-1 blockade with anakinra improved cardiorespiratory fitness in heart failure with preserved ejection fraction. Methods and Results Thirty-one patients with heart failure with preserved ejection fraction and CRP (C-reactive protein) >2 mg/L were randomized to anakinra (100 mg subcutaneously daily, N=21) or placebo (N=10) for 12 weeks. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/CIRCHEARTFAILURE.118.005036DOI Listing
August 2018
3 Reads
5.891 Impact Factor

A Novel Paradigm for Sacubitril/Valsartan: Beta-Endorphin Elevation as a Contributor to Exercise Tolerance Improvement in Rats With Preexisting Heart Failure Induced by Pressure Overload.

J Card Fail 2018 11 19;24(11):773-782. Epub 2018 Oct 19.

Department of Anesthesiology, Pain Medicine and Critical Care, Steward St Elizabeth's Medical Center/Tufts University School of Medicine, Boston, Massachusetts.

Background: Simultaneous angiotensin receptor (AT) blockade and neprilysin inhibition with the use of sacubitril/valsartan has been recently approved to treat patients with heart failure (HF). Therapeutic benefits of this therapy have been attributed to natriuretic peptide elevation and AT receptor blockade. However, that pharmacologic picture may not be complete. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10719164183111
Publisher Site
http://dx.doi.org/10.1016/j.cardfail.2018.10.006DOI Listing
November 2018
6 Reads

Natriuretic peptide family as diagnostic/prognostic biomarker and treatment modality in management of adult and geriatric patients with heart failure: remaining issues and challenges.

J Geriatr Cardiol 2018 Aug;15(8):540-546

Division of Cardiology, Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, United States.

B-type natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP), the key members of natriuretic peptide family have been recommended as the gold standard biomarkers for the diagnosis and prognosis of heart failure (HF) according to the current clinical guidelines. However, recent studies have revealed many previously unrecognized features about the natriuretic peptide family, including more accurate utilization of BNP and NT-proBNP in diagnosing HF. The pathophysiological mechanisms behind natriuretic peptide release, breakdown, and clearance are very complex and the diverse nature of circulating natriuretic peptides and fragments makes analytical detection particularly challenging. Read More

View Article

Download full-text PDF

Source
http://www.jgc301.com/ch/reader/view_abstract.aspx?file_no=2
Publisher Site
http://dx.doi.org/10.11909/j.issn.1671-5411.2018.08.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188938PMC
August 2018
8 Reads
1.060 Impact Factor

Cholesteryl ester transfer protein (CETP), HDL capacity of receiving cholesterol and status of inflammatory cytokines in patients with severe heart failure.

Lipids Health Dis 2018 Oct 20;17(1):242. Epub 2018 Oct 20.

Servico de Prevencao e Reabilitacao Cardiovascular, Instituto do Coracao, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.

Background: Heart failure (HF) courses with chronic inflammatory process and alterations in lipid metabolism may aggravate the disease. The aim was to test whether the severity of HF, using brain natriuretic peptide (BNP) as a marker, is associated with alterations in functional aspects of HDL, such as lipid transfer, cholesterol ester transfer protein (CETP) and lecithin-cholesterol acyltransferase (LCAT) concentration.

Methods: Twenty-five HF patients in NYHA class I/II and 23 in class III/IV were enrolled. Read More

View Article

Download full-text PDF

Source
https://lipidworld.biomedcentral.com/articles/10.1186/s12944
Publisher Site
http://dx.doi.org/10.1186/s12944-018-0888-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6195750PMC
October 2018
13 Reads

The efficacy and safety of soluble guanylate cyclase stimulators in patients with heart failure: A systematic review and meta-analysis.

Medicine (Baltimore) 2018 Oct;97(41):e12709

Department of Cardiology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Background: Several randomized controlled trials (RCTs) have been investigated the benefits of soluble guanylate cyclase (sGC) stimulators in the treatment of heart failure, but a comprehensive evaluation is lacking. We performed a meta-analysis to evaluate the efficacy and safety of oral sGC stimulators (vericiguat and riociguat) in patients with heart failure.

Methods: Studies were searched and screened in PubMed, Embase, and Cochrane Library. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00005792-201810120-0005
Publisher Site
http://dx.doi.org/10.1097/MD.0000000000012709DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6203591PMC
October 2018
2 Reads